Jefferies Reiterates Buy on HealthSouth Corporation, Raises PT to $33

Jefferies reiterated Buy on HealthSouth Corporation HLS. At the same time, Jefferies raised its price target to $33 from $30. In a research report published today, Jefferies states, "We think HLS remains a compelling investment supported by favorable demographic trends, non-discretionary volumes, and consistent management execution. HLS's guidance appears conservative to us and could yield earnings upside surprises in the coming quarters. Reiterate Buy/PT $33 (from $30)." On Thursday, HealthSouth added 1.83% to its value to close the day at $27.86.